	US 12,264,340 B2
	Polypeptide having phospholipase C activity and use thereof
Yaoji Xuan, Shanghai (CN); Qiwen Niu, Shanghai (CN); and Zhengjun Xu, Shanghai (CN)
Assigned to Wilmar (Shanghai) Biotechnology Research & Development Center Co., Ltd, Shanghai (CN)
Appl. No. 17/419,082
Filed by Wilmar (Shanghai) Biotechnology Research & Development Center Co., Ltd, Shanghai (CN)
PCT Filed Dec. 27, 2019, PCT No. PCT/CN2019/128973 § 371(c)(1), (2) Date Jun. 28, 2021, PCT Pub. No. WO2020/135658, PCT Pub. Date Jul. 2, 2020.
Claims priority of application No. 201811625457.6 (CN), filed on Dec. 28, 2018.
Prior Publication US 2022/0073889 A1, Mar. 10, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 9/16 (2006.01); C11B 3/00 (2006.01)

CPC C12N 9/16 (2013.01) [C11B 3/003 (2013.01); C12Y 301/04003 (2013.01)]

13 Claims

1. A mutant phospholipase C polypeptide, wherein the polypeptide sequence has at least 95% identity with the amino acid sequence of SEQ ID NO:4, and has proline, isoleucine, threonine, glycine, and tyrosine, respectively, at positions 6, 8, 10, 104, and 205, with reference to SEQ ID NO: 4.